The weight loss dose is 2.4 mg, more than double
Some report renewed weight loss with each switch
Compounding in times of shortage As access to GLP-1 continues to fluctuate, compounding pharmacies can help address this shortage
Resistance training at least twice per week is the minimum structural input for protecting lean mass during weight loss
Due to the ability to ameliorate IR and lipotoxicity in the pathogenesis of NASH, GLP-1R is a potential therapeutic target for NASH
The following CVOTs, relative to DPP-4i and GLP-1RAs, have been identified and included in this review: EXAMINE, SAVOR-TIMI53, TECOS, CARMELINA, CAROLINA, ELIXA, SUSTAIN 6, EXSCEL, HARMONY, LEADER, PIONEER 6, REWIND, and AMPLITUDE-O [47,48,49, 53, 54, 56,57,58,59,60,61,62,63]